MSC-derived Extracellular Vesicles for Delivery of Osteoarthritis Drugs

Overview

Human MSC-derived extracellular vesicles will be used to load OA drugs and injected into joint cavity for OA treatment. The research findings are expected to reduce OA-associated joint pain, promote joint regeneration, and reduce the burden of OA treatment associated with an aging population.

Problem addressed

Pain and physical disability caused by osteoarthritis

Innovation

Extracellular vesicle-based cell-free therapies
New delivery strategy for osteoarthritis drug
Large-scale production of MSC-derived microvesicles

Key impact

Effectively prolong drug retention in joint cavity
Lower cost of osteoarthritis treatment
Improve osteoarthritis treatment outcomes
Reduce burden of osteoarthritis on patients and healthcare system

Center for Neuromusculoskeletal Restorative Medicine (CNRM) is a multi-disciplinary, international consortium devoted to the application of convergent principles and technologies of biomedical science and engineering to restore structure and function to neuromusculoskeletal tissues and organs injured, diseased and degenerated due to aging, for the maintenance of mobility and enhancement of quality of life through biomedical research and development.

The Center based at the Hong Kong Science and Technology Park (HKSTP), combines the talents and expertise in stem cells, biomaterials, 3D bioprinting, tissue engineering, and personalized and translational medicine from The Chinese University of Hong Kong (CUHK) and the Karolinska Institutet (KI).

Enquiry